NuCana plc News - N04A | Aktien Tradegate (DE)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Remains on Track to Initiate an Expansion Study of...

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update Presented Encouraging Phase 2 Data on NUC-7738 in Combination...

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Patients with...

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE...

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the...

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis...

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024 Anticipated...

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at the Jefferies Global Healthcare Conference NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA...

NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit

NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana...

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024...

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc...

NuCana Announces Completion of ADS Ratio Change

NuCana Announces Completion of ADS Ratio Change EDINBURGH, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA...

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy...

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Announces Plan to Implement ADS Ratio Change EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA...

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373...

Rendering Error

Error: 507

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NuCana plc (N04A)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

N04A Nachrichten

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Announces Completion of ADS Ratio Change

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

N04A Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NuCana plc (N04A) News

NuCana plc (N04A)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

N04A Nachrichten

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Announces Completion of ADS Ratio Change

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

N04A Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen